NY-ESO-1 and cancer immunotherapy.
- Author:
Ji-run PENG
1
;
Xi-sheng LENG
Author Information
1. Center of Hepatobiliary Surgery, Peking University People's Hospital, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Antigens, Neoplasm;
genetics;
immunology;
therapeutic use;
Cancer Vaccines;
immunology;
therapeutic use;
Clinical Trials as Topic;
Humans;
Immunotherapy;
Membrane Proteins;
genetics;
immunology;
therapeutic use;
Neoplasms;
genetics;
immunology;
therapy
- From:
Acta Academiae Medicinae Sinicae
2008;30(4):371-377
- CountryChina
- Language:Chinese
-
Abstract:
NY-ESO-1 is an important member of cancer-testis antigen family and is widely distributed among many cancer types. As a tumor-specific antigen with the strongest immunogenicity so far identified, it can induce spontaneous antibody and T-cell responses in patients with NY-ESO-1-positive tumors. Therefore, it has been a good vaccine candidate in the immunotherapy against many malignancies. This article reviews the recent research advances in NY-ESO-1 and its relevant vaccines.
